Paclitaxel for the adjuvant treatment of early node-positive breast cancer

View the summary and implementation tools

This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta108

1 Guidance

This guidance replaces paragraph 1.3 of Taxanes for the treatment of breast cancer (NICE technology appraisal guidance 30) issued in September 2001 [Replaced by NICE clinical guideline 81].

CG80 Early and locally advanced breast cancer updates the recommendations contained in this appraisal.

For details, see 'About this guidance'.

1.1 Paclitaxel, within its licensed indication, is not recommended for the adjuvant treatment of women with early node-positive breast cancer.